DRUG PRICE COMPETITION AND PATENT TERM RESTORATION ACT

Bills and resolutions

FDA: prevent inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and provide incentives for drug innovation (see S. 344), S919 [6FE] (see H.R. 990), H1389 [6FE]